Expanding Exclusive Implant Options for Craniomaxillofacial Surgeries

/PRNewswire/ -- Poriferous, LLC, a prominent global producer of Su-Por craniomaxillofacial and patient-specific implants, has secured its patent for its groundbreaking DuraBloc technology from the U.S. Patent and Trademark Office (USPTO), U.S. Patent No. 12,653,677, issued on June 16, 2026.

This newest patent strengthens the company's growing portfolio of proprietary innovations, solidifying its worldwide standing as a pioneer in healthcare advancements and enabling quicker, simpler, and more cost-effective access to high-quality craniomaxillofacial implants.

Poriferous produces Su-Por implants from biocompatible, porous polyethylene. The material forms an interconnecting, omnidirectional pore structure that encourages fibrovascular ingrowth and integration with patient tissue for enduring outcomes.

Su-Por porous polyethylene material can be sculpted, trimmed, and feathered within the sterile field, readily drilled and firmly secured, supporting screws and plates without cracking risk. Advanced Retained Shape Memory, a feature exclusive to Su-Por biomaterial, ensures implants retain their shape after contouring and forming.

Su-Por Patient-Specific Implants are crafted from each patient's unique anatomy for superior, lasting results in reconstructive and augmentation procedures. DuraBloc technology broadens Poriferous' expanding range of patented solutions.

Created through a specialized process, DuraBloc technology includes a smooth, nonporous underside while preserving the porous polyethylene structures of Su-Por implants. As with all Su-Por implants, the porous polyethylene materials can accept antibiotics during surgery to lower infection risk; fibrovascular ingrowth enables the patient's immune system to provide ongoing infection prevention. The distinctive dual-sided DuraBloc design supports fibrovascular ingrowth while minimizing unwanted tissue adhesion for simpler removal.

Available only through Poriferous' Patient-Specific Implants program, DuraBloc implants permit a 50 percent lower flange profile, delivering improved cosmetic fit and more natural outcomes without reducing fixation strength.

As Aaron Noble, CEO and Founder, notes, "We collaborate with surgeons to develop and refine our broad selection of implants. Our newly patented DuraBloc technology meets a continuing demand for implants that can be extracted more readily. DuraBloc encourages tissue ingrowth for natural results without hindering the removal process."

To discover more about Poriferous and its patented advancements, please visit the company website.

About Poriferous

Poriferous was established with an ambitious goal: to drive innovation in surgical implants and deliver the quality outcomes patients deserve. As a focused porous polyethylene implant manufacturer supported by extensive research and partnerships with top surgeons, we develop premium Su-Por implants engineered for smooth tissue integration, stability, and sustained success. Su-Por implants are a preferred option among surgeons globally, assisting patients of every age in restoring confidence, function, and quality of life.

MEDIA CONTACT:
Name: Ara Wilson
Email: [email protected]
Phone: (918) 706-5370

SOURCE Su-Por